Condition (MeSH)
Cranial Nerve Neoplasms
ClinicalTrials.gov lists 207 trials for Cranial Nerve Neoplasms or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 27.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
1 more section with rows
When did Cranial Nerve Neoplasms trials start? (33)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 13
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 10 |
| 2025 | 5 |
| 2024 | 5 |
| 2023 | 1 |
| 2022 | 9 |
| 2021 | 8 |
| 2020 | 6 |
| 2019 | 11 |
| 2018 | 13 |
| 2017 | 12 |
Showing 10 of 33 earlier years.
Forecast of the full-year count, planned starts included, not rows of this table: about 12 trials starting in 2026 and about 8 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Prediction, not a registry value: median of 36 months from start to primary completion across 13 trials still running at the 2026-10-09 snapshot; registered median of 44 months across 129 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Cranial Nerve Neoplasms trials in? (9)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 56 |
| Phase 1/2 | 8 |
| Phase 2 | 43 |
| Phase 2/3 | 1 |
| Phase 3 | 7 |
| Phase 4 | 2 |
| Not applicable | 50 |
| Observational | 39 |
| Expanded access | 1 |
How many Cranial Nerve Neoplasms trials are recruiting? (10)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 5 |
| Recruiting | 21 |
| Enrolling by invitation | 3 |
| Active, not recruiting | 9 |
| Completed | 112 |
Showing 5 of 10 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Cranial Nerve Neoplasms trials? (5)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 27 |
| Children's Oncology Group | 12 |
| Pediatric Brain Tumor Consortium | 8 |
| National Institutes of Health Clinical Center (CC) | 3 |
| Akouos, Inc. | 2 |
Which drugs are being tested for Cranial Nerve Neoplasms? (5)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Selumetinib | 5 |
| Irinotecan | 4 |
| EVEROLIMUS | 4 |
| O6-Benzylguanine | 3 |
| Busulfan | 3 |
Interventions as named in the registry (10)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| or carboplatin | 12 |
| SOC: Temozolomide | 12 |
| Filgrastime (G-CSF) | 8 |
| Etoposid | 7 |
| Bevacizumab 1 | 7 |
Showing 5 of 10 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Cranial Nerve Neoplasms trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Seizure | 15 | 7 |
| Pneumonia | 13 | 2 |
| Fatigue | 11 | 3 |
| Headache | 11 | 5 |
| Dehydration | 10 | 5 |
Showing 5 of 10 adverse events.
Which publications cover Cranial Nerve Neoplasms? (18)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Trigeminal Ganglioneuroma: A Rare Case of Trigeminal Neuralgia Caused by Cerebellopontine Angle Tumor. | World neurosurgery | 2017 | Yes |
| Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas. | Journal of neuro-oncology | 2015 | Yes |
| The olfactory system. | Diagnostic and interventional imaging | 2013 | Yes |
| Na(v)1.7 sodium channel expression in human lingual nerve neuromas. | Archives of oral biology | 2007 | Yes |
| Long-term follow up of 69 patients treated for optic pathway tumours before the chemotherapy era. | Archives of disease in childhood | 1998 | Yes |
Showing 5 of 18 publications.
Sub-conditions in MeSH (2)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.